TITLE

Human papillomavirus 16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia in young women

AUTHOR(S)
Nanda, Kavita
PUB. DATE
December 2009
SOURCE
ACP Journal Club;12/15/2009, Vol. 151 Issue 6, p4
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information about a clinical trial which examines the effectiveness of an AS04-adjuvanted vaccine against human papillomavirus (HPV) 16/18 in preventing cervical intraepithelial neoplasia (CIN) in young women. 18,729 healthy women of 15 to 25 years were selected from 135 centers in 14 countries. The results show that an AS04-adjuvanted vaccine against human papillomavirus 16/18 can prevent CIN in young women.
ACCESSION #
47420849

 

Related Articles

  • Two Doses of HPV Vaccine May Be Sufficient. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;10/19/2011, Vol. 306 Issue 15, p1643 

    The article reports on the adequacy of two doses of a human papillomavirus (HPV) vaccine to protect against cervical cancer based on a clinical trial in Costa Rica conducted by Aimée R. Kreimer et al. published in the "Journal of the National Cancer Institute" in 2011.

  • Choice of cancer vaccine is branded a missed opportunity by charities. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1456 

    The article discusses how health charities are criticizing the adoption of the drug Cervarix into national immunisation initiatives in Great Britain. Cervarix, developed by the pharmaceutical firm GlaxoSmithKline is designed to vaccinate women against human papillomaviruses, which can cause...

  • An Analysis of HPV Vaccine Efficacy in Preventing Cervical Cancer. Ershler, William B. // Clinical Oncology Alert;Jul2007, Vol. 23 Issue 7, p49 

    CERVICAL CANCER CONTINUES TO BE THE SECOND LEADING cause of cancer-related death in women under 45 years of age, resulting in more than 200,000 deaths per year worldwide. It has been well established that a significant majority of these cancers (approximately 70%) are caused by Human Papilloma...

  • HPV vaccine strategies: the cost of HPV and the choice of vaccine. Morris, Sheldon R. // Sexually Transmitted Infections;Sep2009, Vol. 85 Issue 5, p315 

    The author reflects on the strategies for selecting the right human papillomavirus (HPV) vaccines for the prevention of cervical cancer. He cites efficacious vaccines that are approved in many developed countries which include Merck quadrivalent HPV 6/11/16/18 (Gardisil) and GSK bivalent HPV...

  • Lessons from the Failure of Human Papillomavirus Vaccine State Requirements. Schwartz, J. L.; Caplan, A. L.; Faden, R. R.; Sugarman, J. // Clinical Pharmacology & Therapeutics;Dec2007, Vol. 82 Issue 6, p760 

    The licensure in 2006 of a vaccine against the subtypes of human papillomavirus (HPV) responsible for the majority of cervical cancers and genital warts was heralded as a watershed moment for vaccination, cancer prevention, and global health.1 A safe and effective vaccine against HPV has long...

  • Increased screening best option for cervical cancer prevention in Thailand.  // PharmacoEconomics & Outcomes News;9/3/2011, Issue 636, p1 

    The article presents the findings of an analysis which showed that human papillomavirus (HPV) vaccines are unlikely to be cost effective in reducing the problem of cervical cancer in Thailand. It references a study by N. Praditsitthikorn and colleagues, published in the September 2011 issue of...

  • DETECCIÓN DE VIRUS PAPILOMA HUMANO EN LA PREVENCIÓN DEL CÁNCER CÉRVICO-UTERINO. PICCONI, MARÍA ALEJANDRA // Medicina (Buenos Aires);2013, Vol. 73 Issue 6, p585 

    Cervical cancer (CC), which is strongly associated to high-risk human papillomavirus (hr-HPV) infection, continues being a significant health problem in Latin America. The use of conventional cytology to detect precancerous cervical lesions has had no major impact on reducing CC incidence and...

  • HPV Vaccination in India: Critical Appraisal. Nigam, Aruna; Saxena, Pikee; Acharya, Anita S.; Mishra, Archana; Batra, Swaraj // ISRN Otolaryngology;2014, p1 

    Cervical cancer is the third most common cancer in women worldwide. The role of human papilloma virus (HPV) in the genesis of cervical carcinoma is well documented. The HPV 16 and 18 are found to be most commonly associated with invasive cervical carcinoma. The advent of cervical carcinoma...

  • Commentary on Statement on Human Papillomavirus Test Utilization. Cox, John Thomas; Moriarty, Ann T.; Castle, Philip E. // Archives of Pathology & Laboratory Medicine;Aug2009, Vol. 133 Issue 8, p1192 

    The authors reflect on the utilization of human papillomavirus (HPV) test to prevent cervical cancer in young women. They point out that HPV testing should use an equivalent test and should be applied for high-risk HPV (HR-HPV) types only in order to identify its clinical benefit and adequate...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics